IRIS Institutional Research Information System - OPENBS Open Archive UniBS

BOSSI, Paolo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.260
EU - Europa 3.164
AS - Asia 3.074
AF - Africa 24
OC - Oceania 17
SA - Sud America 17
Continente sconosciuto - Info sul continente non disponibili 4
Totale 17.560
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.218
CN - Cina 1.030
UA - Ucraina 841
SG - Singapore 825
HK - Hong Kong 665
IT - Italia 416
IE - Irlanda 379
DE - Germania 362
PL - Polonia 339
TR - Turchia 322
EE - Estonia 292
GB - Regno Unito 186
FI - Finlandia 147
SE - Svezia 88
ID - Indonesia 79
VN - Vietnam 60
IN - India 53
CA - Canada 37
CZ - Repubblica Ceca 37
FR - Francia 28
AU - Australia 16
EG - Egitto 10
BE - Belgio 9
NL - Olanda 8
CH - Svizzera 7
JP - Giappone 7
MY - Malesia 7
RU - Federazione Russa 7
BR - Brasile 6
LY - Libia 5
AR - Argentina 4
EU - Europa 4
MA - Marocco 4
MK - Macedonia 4
ES - Italia 3
HR - Croazia 3
IR - Iran 3
RO - Romania 3
TH - Thailandia 3
EC - Ecuador 2
IL - Israele 2
JM - Giamaica 2
KG - Kirghizistan 2
KR - Corea 2
MX - Messico 2
PH - Filippine 2
PK - Pakistan 2
TN - Tunisia 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BO - Bolivia 1
CL - Cile 1
CO - Colombia 1
DK - Danimarca 1
FK - Isole Falkland (Malvinas) 1
IQ - Iraq 1
IS - Islanda 1
JO - Giordania 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MD - Moldavia 1
MU - Mauritius 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
SA - Arabia Saudita 1
SI - Slovenia 1
TW - Taiwan 1
Totale 17.560
Salva come PNG Salva come JPEG
Città #
Fairfield 2.231
Ashburn 1.086
Seattle 903
Woodbridge 898
Jacksonville 846
Houston 769
Cambridge 694
Singapore 680
Wilmington 668
Hong Kong 659
Princeton 636
Chandler 416
Dublin 337
Warsaw 337
New York 326
Istanbul 309
Tallinn 292
Ann Arbor 282
Beijing 219
Des Moines 157
Nanjing 156
San Diego 150
Helsinki 133
Brescia 106
Jakarta 76
Shenyang 69
London 61
Changsha 60
Dong Ket 58
Shanghai 57
Nanchang 53
Hebei 52
Jinan 52
Jiaxing 49
Tianjin 46
Menlo Park 43
Milan 41
Pune 40
Brno 33
Rome 31
Kilburn 26
Los Angeles 26
Ningbo 26
Norwalk 22
Toronto 21
Romola 18
Taizhou 18
Hangzhou 17
Boardman 16
Haikou 16
Munich 16
San Francisco 16
Guangzhou 14
Dearborn 13
Rende 13
New Bedfont 12
Washington 11
Cairo 10
Chiswick 10
Frankfurt am Main 10
Lanzhou 10
Zhengzhou 10
Canberra 9
Fort Worth 9
Hanover 8
Prineville 8
Brooklyn 7
Brussels 7
Cazzago San Martino 7
Hounslow 7
Lappeenranta 7
Santa Clara 7
Verona 7
Fuzhou 6
Melbourne 6
Taiyuan 6
Augusta 5
Dalmine 5
Lancaster 5
Leawood 5
Prescot 5
Wandsworth 5
Arezzo 4
Bonn 4
Paris 4
Petaling Jaya 4
Redwood City 4
Tokyo 4
Turin 4
Acton 3
Amsterdam 3
Benghazi 3
Berlin 3
Central 3
Gunzenhausen 3
Kocaeli 3
Kunming 3
Lucca 3
Markham 3
Montreal 3
Totale 14.654
Salva come PNG Salva come JPEG
Nome #
Systematic review of photobiomodulation for the managementof oral mucositis in cancer patients and clinical practice guidelines 171
Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines-part 1: vitamins, minerals, and nutritional supplements. 171
Prognostic Nomograms in Oral Squamous Cell Carcinoma: The Negative Impact of Low Neutrophil to Lymphocyte Ratio 165
Pretreatment DWI with Histogram Analysis of the ADC in Predicting the Outcome of Advanced Oropharyngeal Cancer with Known Human Papillomavirus Status Treated with Chemoradiation 153
Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement 148
Clinical and histological prognostic factors of recurrent and/or metastatic salivary gland adenoid cystic carcinoma 143
Tumor biomarkers for the prediction of distant metastasis in head and neck squamous cell carcinoma 131
Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus 126
Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm? 122
Gene expression profiling to improve prognostic characterization of olfactory neuroblastoma and to define new targetable pathways 118
Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement 113
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact 113
Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions 113
Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus 108
Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus 107
Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines - part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents 106
Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor 101
Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma 98
Precision medicine in rare tumors and the need for multicenter trials and international collaboratives: Sinonasal cancer as paradigm 98
The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures 97
CISPLATIN DOSE INTENSITY CORRELATES WITH OUTCOME IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA RECEIVING CONCURRENT CISPLATIN BASED CHEMORADIATION: A MULTI-INSTITUTIONAL EXPERIENCE 97
Investigational drugs for head and neck cancer 97
Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy 95
Malignant tumors of the maxillary sinus: Prognostic impact of neurovascular invasion in a series of 138 patients 95
The 8th TNM classification for oral squamous cell carcinoma: What is gained, what is lost, and what is missing 93
Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma 92
Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer 90
Hope in cancer patients: the relational domain as a crucial factor 90
Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN) 89
Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis 88
The role of systemic therapy in the management of sinonasal cancer: A critical review 88
Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review 87
T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results 85
The Case Volume Issue in Head and Neck Oncology 85
Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers 84
Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma 84
Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study 83
Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy 83
Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma 83
Primary resistances to EGFR inhibitors (EGFRi) in HPV-positive and -negative oropharyngeal squamous cell carcinoma (OSCC) 83
Mining of self-organizing map gene-expression portraits reveals prognostic stratification of HPV-positive head and neck squamous cell carcinoma 83
Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study 82
Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy 81
Genome-wide study of salivary miRNAs identifies miR-423-5p as promising diagnostic and prognostic biomarker in oral squamous cell carcinoma 81
Circulating pretreatment Epstein Barr Virus DNA quantification as a prognostic factor in nasopharyngeal cancer patients in a non endemic area 80
TP53 Mutations and Pathologic Complete Response to Neoadjuvant Cisplatin and Fluorouracil Chemotherapy in Resected Oral Cavity Squamous Cell Carcinoma 80
Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients 80
TP53 mutations in head and neck cancer 80
Gene-expression profiles of primary and metastatic lesions in head and neck squamous cell carcinoma 79
Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma 79
Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma 79
Pain related to cancer treatments and diagnostic procedures: a no man's land? 79
NICSO: Network Italiano Cure di Supporto in Oncologia - Italian Network for Supportive Care in Oncology 79
Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements 79
Multikinase inhibitors in thyroid cancer 79
Assessing Preferences in Patients with Head and Neck Squamous Cell Carcinoma: Phase I and II of Questionnaire Development 79
Comments on "Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: Patterns of failure" by Chan and Coll 78
Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options 78
Searching for Evidence to Support the Use of Ginger in the Prevention of Chemotherapy-Induced Nausea and Vomiting 78
Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients 78
Receptor Tyrosine Kinase Profiles and Human Papillomavirus Status in Oropharyngeal Squamous Cell Carcinoma 78
Folate in head and neck squamous cell cancer chemoprevention: Purposely left out? 77
Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs) 77
Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab 77
Resistance to Hedgehog inhibitor through Smoothened receptor mutation in basal cell carcinoma 77
A NATURAL HISTORY OF A SERIES OF RADIOACTIVE IODINE (131I-RAI)-RESISTANT ADVANCED DIFFERENTIATED THYROID CANCER (DTC) 77
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck 77
Differential impact of cisplatin dose intensity on human papillomavirus (HPV)-related (+) and HPV-unrelated (-) locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC) 76
Prognostic role of PI3KCA and TP53 in HPV-negative oropharyngeal cancers (OPCs) 76
The Benefit of a Multidisciplinary Approach to the Patient Treated with (Chemo) Radiation for Head and Neck Cancer 76
Circulating pretreatment Epstein Barr Virus DNA quantification as a prognostic factor in nasopharyngeal cancer patients in a non endemic area 75
Feasibility and activity of docetaxel, cisplatinum and 5-fluorouracil induction chemotherapy followed by concurrent chemo-radiotherapy (including IMRT) in locally advanced undifferentiated nasopharyngeal cancer (LANPC) 75
Cisplatin dose intensity correlates with outcome in patients with locally advanced head and neck squamous cell carcinoma receiving concurrent cisplatin based chemoradiation: a multi-institutional experience 75
Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma 75
Role of induction chemotherapy in the multimodal management of locally advanced epithelial sinonasal cancer 74
Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients 74
Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis 74
Emerging tyrosine kinase inhibitors for head and neck cancer 74
Induction chemotherapy within a multimodality treatment of nasal cavity and ethmoid sinus malignant epithelial tumours: report of an homogeneous series of patients 74
Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up 74
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 74
OROPHARYNGEAL SQUAMOUS CELL CARCINOMA TREATED WITH RADIOTHERAPY OR RADIOCHEMOTHERAPY: PROGNOSTIC ROLE OF TP53 AND HPV STATUS 73
Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data 73
Italian version of the MD Anderson Symptom Inventory-Head and Neck Module: linguistic validation 72
Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations 72
Radiotherapy for unresectable sinonasal cancers: Dosimetric comparison of intensity modulated radiation therapy with coplanar and non-coplanar volumetric modulated arc therapy 72
Isolating p16-positive/HPV-negative Oropharyngeal Cancer: An Effort Worth Making 72
Gastrointestinal toxicities from targeted therapies: measurement, duration and impact 72
Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer 72
A complete remission with androgen-deprivation therapy in a recurrent androgen recptor-expressing adenocarcinoma of the parotid gland [1] 72
Rapid-Onset Opioids for the Treatment of Breakthrough Cancer Pain: Two Cases of Drug Abuse 72
Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial 71
Postoperative radiotherapy with volumetric modulated arc therapy of lacrimal gland carcinoma: two case reports and literature review 71
New insights in chemotherapy 71
Do not throw the baby out with the bathwater: SELECT a personalized, de-escalated lenvatinib schedule allows response in locally advanced DTC while controlling major drug-related bleeding 71
Lenvatinib-induced renal failure: two first-time case reports and review of literature 71
Dissecting heterogeneity and molecular mechanisms involved in paranasal sinus cancer 70
Comprehensive meta-analysis of publicly available microarray data in head and neck cancer 70
Global cancer control: responding to the growing burden, rising costs and inequalities in access 70
Palifermin in Prevention of Head and Neck Cancer Radiation-Induced Mucositis: Not Yet a Definitive Word on Safety and Efficacy Profile 70
Totale 8.807
Salva come PNG Salva come JPEG
Categoria #
all - tutte 136.462
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 136.462
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.243 0 0 0 0 0 386 485 392 301 383 206 90
2020/20215.199 64 476 246 999 298 729 152 519 345 723 284 364
2021/20222.337 116 253 56 283 109 212 76 202 120 195 201 514
2022/20231.518 359 89 46 113 92 464 8 96 144 26 37 44
2023/20242.385 64 36 117 107 122 577 90 137 665 39 33 398
2024/20251.837 32 21 69 1.028 543 144 0 0 0 0 0 0
Totale 17.960